ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
ANI Pharmaceuticals (Nasdaq: ANIP) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens.
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before the market opens. A conference call and live webcast at 8:00 a.m. ET will discuss the results, with replay available for 12 months.
Executives on the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. The webcast and replay will be available under Investors > Events and Presentations at www.anipharmaceuticals.com. Dial-in details include toll-free U.S. access and Conference ID 5230834.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ANIP
On Feb 13, the day this news came out, ANIP closed 0.86% above the previous close.
Data tracked by StockTitan Argus for the Feb 13 session.
Key Figures
- Earnings call date
- February 27, 2026
- Q4 and full year 2025 results release
- Earnings call time
- 8:00 a.m. ET
- Start time for Q4/FY 2025 conference call
- Toll-free number
- 800-274-8461
- U.S. dial-in for February 27, 2026 earnings call
- Conference ID
- 5230834
- Access code for Q4/FY 2025 earnings call
- Webcast replay duration
- 12 months
- Availability of archived earnings webcast
- Q3 2025 net revenues
- $227.8M
- Record quarter reported November 7, 2025
- Q2 2025 net revenues
- $211.4M
- Record quarter reported August 8, 2025
- Q1 2025 revenues
- $197.1M
- Record quarter reported May 9, 2025
Previous Earnings Reports
-
Record Q3 revenues and earnings with raised 2025 guidance.
-
Announcement of Q3 2025 results release and conference call details.
-
Record Q2 revenues, strong Rare Disease growth, guidance raised.
-
Scheduling of Q2 2025 results release and earnings call access details.
-
Record Q1 revenues, strong Rare Disease and Generics growth, guidance raised.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows:
| Date | Friday, February 27, 2026 |
| Time | 8:00 a.m. ET |
| Toll free (U.S.) | 800-274-8461 |
| Conference ID | 5230834 |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 12 months following the event.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.